Please provide your email address to receive an email when new articles are posted on . SGLT2 and GLP-1 agents were linked to lower risk of kidney-related outcomes for adults with type 2 diabetes and ...

Use of sodium-glucose cotransporter-2 inhibitors was linked to significantly reduced risk for adverse kidney, cardiovascular and hepatic outcomes in patients with type 2 diabetes and cirrhosis, ...

In a real-world study of patients aged 60 years or older with diabetes, SGLT2 inhibitor users experienced a significantly slower decline in estimated glomerular filtration rate compared with DPP4 ...

SGLT2 inhibitors showed significantly improved mortality benefits compared with DPP-4 inhibitors in patients with diabetic kidney disease (DKD) in a large target trial emulation study that adds ...

SGLT2 inhibitors combat inflammation and slow kidney disease by elevating S-adenosylmethionine (SAM) levels, which suppress inflammatory gene activity through epigenetic modification. The benefits of ...

GLP1 agonists and SGLT2 inhibitors have similar long-term safety profiles and tolerability in kidney transplant recipients, and SGLT2 inhibitor use for post-transplant diabetes is associated with ...

Observational study data suggest that SGLT2 inhibitor use reduces risks for kidney and cardiovascular events even in patients with an eGFR less than 15 mL/min/1.73 m2 who have type 2 diabetes.

Author: Deepak L. Bhatt, MD, MPH, MBA, Director of Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai ...

Adding an SGLT2 inhibitor to standard care did not improve clinical outcomes in critically ill patients with acute organ dysfunction, an open-label randomized trial involving intensive care units ...